Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 250 entries
View as:

Efficacy and Safety of Chidamide in CBF Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03031262 Org: User:
Start: 02/08/17 End: 12/30/27 Due: 12/30/28

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Phase: N/A Priority: Normal
NCT ID: NCT02858804 Org: User:
Start: 01/31/16 End: 06/30/20 Due: 06/30/21

Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.

Phase: N/A Priority: Normal
NCT ID: NCT01579110 Org: User:
Start: 04/30/12 End: 04/30/16 Due: 04/30/17

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06504199 Org: User:
Start: 07/18/24 End: 12/31/28 Due: 12/31/29

Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06695741 Org: User:
Start: 11/01/24 End: 06/30/27 Due: 06/30/28

Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06769568 Org: User:
Start: 01/31/25 End: 09/30/28 Due: 09/30/29

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02523976 Org: User:
Start: 08/01/15 End: 12/31/21 Due: 12/31/22

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT05849740 Org: User:
Start: 05/22/23 End: 10/31/27 Due: 10/31/28

Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model

Phase: N/A Priority: Normal
NCT ID: NCT06880419 Org: User:
Start: 03/31/25 End: 12/31/26 Due: 12/31/27

Gene Therapy for Chinese Hemophilia B

Phase: N/A Priority: Normal
NCT ID: NCT04135300 Org: User:
Start: 10/16/19 End: 01/07/22 Due: 01/07/23

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Phase: N/A Priority: Normal
NCT ID: NCT06882057 Org: User:
Start: 03/31/25 End: 06/30/33 Due: 06/30/34

Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

Phase: N/A Priority: Normal
NCT ID: NCT04688736 Org: User:
Start: 01/01/21 End: 06/30/26 Due: 06/30/27

Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Phase: N/A Priority: Normal
NCT ID: NCT06547944 Org: User:
Start: 01/01/24 End: 12/01/26 Due: 12/01/27

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06158269 Org: User:
Start: 12/31/23 End: 12/31/27 Due: 12/31/28

Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05536700 Org: User:
Start: 12/31/21 End: 12/31/22 Due: 12/31/23

The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients

Phase: N/A Priority: Normal
NCT ID: NCT06880380 Org: User:
Start: 03/07/25 End: 07/01/26 Due: 07/01/27

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02975687 Org: User:
Start: 11/30/16 End: 12/31/18 Due: 12/31/19

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05739409 Org: User:
Start: 02/28/23 End: 08/31/24 Due: 08/31/25

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06427330 Org: User:
Start: 07/02/24 End: 06/30/26 Due: 06/30/27

Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

Phase: N/A Priority: Normal
NCT ID: NCT06744504 Org: User:
Start: 01/10/25 End: 12/01/29 Due: 12/01/30

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Phase: N/A Priority: Normal
NCT ID: NCT02267993 Org: User:
Start: 10/31/14 End: 08/31/18 Due: 08/31/19

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05654779 Org: User:
Start: 12/12/22 End: 09/26/23 Due: 09/26/24

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05549973 Org: User:
Start: 09/30/22 End: 07/31/24 Due: 07/31/25

Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT

Phase: N/A Priority: Normal
NCT ID: NCT05914701 Org: User:
Start: 07/01/23 End: 12/31/24 Due: 12/31/25

The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT06504186 Org: User:
Start: 07/31/24 End: 10/31/26 Due: 10/31/27